Treatment of oral dryness in Sjögren's syndrome;Traitement actuel de la xérostomie au cours du syndrome de Sjögren

Revue de Medecine Interne

Volumn 25, Issue 4, 2004, Pages 287-293

  Mariette, X ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Cevimeline; Pilocarpine; Sjogren's syndrome; Syndrome de Gougerot Sj gren; TNF; Xerostomia; X rostomie

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B DEOXYCHOLATE; ANETHOLE TRITHIONE; AZATHIOPRINE; BROMHEXINE; CEVIMELINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYCLOPHOSPHAMIDE; FLUCONAZOLE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MUSCARINIC AGENT; PILOCARPINE; RITUXIMAB; SURFARLEM;

CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG EFFECT; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATHOPHYSIOLOGY; REVIEW; SALIVATION; SJOEGREN SYNDROME; TREATMENT OUTCOME; XEROSTOMIA;

EID: 1842475288     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.revmed.2003.09.017     Document Type: Short Survey

References (28)

1. e édition Maddison P.J., Isenberg D.A., Woo P., Glass D.N. Oxford Textbook of Rheumatology. volume 2:1997;1301-1317 Oxford Medical Publications, Oxford.
2. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 61:2002;554-558.
3. Tribout B., Gras-Champel V., Pannier M., Andréjak M. Physiologie et pharmacologie des sécrétions lacrymale et salivaire. Rev Prat. 51:2001;133-139.
4. Pathak A., Tran M.A., Montastruc J.L. Atropine. Principes et règles d'utilisation. Rev Prat. 51:2001;59-63.
5. Haddad E.B., Rousel J., Lindsay M.A., Barnes P.J. Synergy between TNF- and IL-1 in inducing transcriptionnal down-regulation of muscarinic M2 receptor gene expression. Involvement of protein kinase A and ceramide pathways. J Biol Chem. 271:1996;32586-32592.
6. Waterman S.A., Gordon T.P., Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum. 43:2000;1647-1654.
7. Steinfeld S., Cogan E., King L.S., Agre P., Kiss R., Delporte C. Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjögren's syndrome patients. Lab Invest. 81:2001;143-148.
8. Tsubota K., Hirai S., King L.S., Agre P., Kiss R., Delporte C. Deffective cellular trafficking of lacrimal gland aquaporin-5 in Sjögren's syndrome. Lancet. 357:2001;688-689.
9. Nguyen K.H.T., Brayer J., Cha S., et al. Evidence for antimuscarinic acetylcholine receptor antibody-mediatec secretory dysfunction in NOD mice. Arthritis Rheum. 43:2000;2297-2306.
10. Beroukas D., Hiscock J., Jonsonn R., Waterman S.A., Gordon T.P. Subcellular distribution of aquaporin 5 in salivary glands in primary Sjögren's syndrome. Lancet. 358:2001;1875-1876.
11. Price E.J., Venables P.J.W. Dry eyes and mouth syndrome - A subgroup of patients presenting with sicca symptoms. Rheumatology. 41:2002;416-422.
12. Mariette X., Caudmont C., Berge E., Desmoulins F., Pinabel F. Dry eyes and mouth syndrome or sicca, asthenia and polyalgia syndrome? Rheumatology. 42:2003;914-915.
13. Mariette X. Current and potential treatments for primary Sjogren's syndrome. Joint Bone Spine. 69:2002;363-366.
14. Frost-Larsen K., Isager H., Manthorpe R. Sjögren's syndrome treated with bromhexine: a randomised clinical study. Br Med J. 1:(6127):1978;1579-1581.
15. Schiodt M., Oxholm P., Jacobsen A. Treatment of xerostomia in patients with primary Sjogren's syndrome with sulfarlem. Scand J Rheumatol Suppl. 61:1986;250-252.
16. Vivino F.B., Al-Hashimi I., Khan Z., Leveque F.G., Salisbury P.L. III, Tran-Johnson T.K. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome. A randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Int Med. 159:1999;174-181.
17. Johnson J.T., Ferretti G.A., Nethery W.J., Valdez I.H., Fox P.C., Ng D., Muscoplat C.C., Gallagher S.C. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med. 329:1993;390-395.
18. Petrone D., Condemi J.J., Fife R., Gluck O., Cohen S., Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 46:2002;748-754.
19. Kruize A.A., Hené R.J., Kallenberg C.G.M., Van Bijsterveld O.P., Van der Heide A., Kater L., et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis. 52:1993;360-364.
20. Skopouli F.N., Jagiello P., Tsifetaki N., Moutsopoulos H.M. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol. 14:1996;555-558.
21. Price E.J., Rigby S.P., Clancy U., Venables P.J. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome. J Rheumatol. 25:1998 May;896-899.
22. Miyawaki S., Nishiyama S., Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren's syndrome. Intern Med. 38:1999;938-943.
23. Izumi M., Eguchi K., Nakamura H., Takagi Y., Kawabe Y., Nakamura T. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjogren's syndrome. Ann Rheum Dis. 57:1998;464-469.
24. Ship J.A., Fox P.C., Michalek J.E., Cummins M.J., Richards A.B. Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res. 19:1999;943-951.
25. Tornwall J., Fox H., Edwards C., Fox R. Treatment with pegylated recombinant methionyl human soluble tumor necrosis factor-type 1 receptor (PEG-s TNF R1) prevents development of Sjögren's syndrome and diabetes in the NOD mouse model. Arthritis Rheum. 42:(Suppl):1999;S403. (Abst).
26. Steinfeld S.D., Demols P., Salmon I., Kiss R., Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum. 44:2001;2371-2375.
27. Zandbelt M.M., De Wilde P.C.M., Van Damme P.A., Hoyng C., Van de Putte L.B.A., Van den Hoogen F.H.J. Etanercept in the treatment of primary Sjögren's syndrome: a pilot study. Ann Rhem Dis. 62:(suppl 1):2003;OP0057.
28. Mariette X. Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection could share a common pathogenesis: chronic stimulation of rheumatoïd factor B cells. Ann Rheum Dis. 60:2001;1007-1010.